Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.09 USD | 0.00% | +6.09% | -45.43% |
May. 02 | Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference | CI |
Apr. 04 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 33.07M |
---|---|---|---|---|---|
Net income 2024 * | -15M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.15
x | P/E ratio 2025 * |
-1.27
x | Employees | 4 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.8% |
Latest transcript on Acurx Pharmaceuticals, Inc.
1 week | +6.09% | ||
Current month | -5.00% | ||
1 month | +18.08% | ||
3 months | -30.10% | ||
6 months | -38.53% | ||
Current year | -45.43% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Shawah
FOU | Founder | 57 | 17-06-30 |
David Luci
FOU | Founder | 57 | 17-06-30 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert de Luccia
FOU | Founder | 78 | 17-06-30 |
Joseph Scodari
BRD | Director/Board Member | 71 | 21-06-23 |
Thomas Harrison
BRD | Director/Board Member | 76 | 21-06-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 2.09 | 0.00% | 54,394 |
24-05-13 | 2.09 | +2.96% | 12,200 |
24-05-10 | 2.03 | +0.50% | 16,796 |
24-05-09 | 2.02 | +4.12% | 75,258 |
24-05-08 | 1.94 | -1.52% | 20,197 |
Delayed Quote Nasdaq, May 14, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.43% | 33.07M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.24% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- ACXP Stock